Overview of Clinical Stage Therapeutic Area
Relapsed/Refractory B cell non-Hodkin Lymphoma:
Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. The refractory disease may be a disease that is getting worse or staying the same. Relapsed non-Hodgkin lymphoma (NHL) is NHL that responded to treatment but then returns.
CD19 is the earliest differentiation antigen of the B lineage and is ubiquitously expressed on all types of B lymphocytes except plasma cells, thereby representing an attractive target for B-cell non-Hodgkin lymphomas (NHL) or leukemia of B-cell origin.
Defect: Cancer/Lymphoma
Treatment Approach: CB-010 is an off-the-shelf allogeneic anti-CD19, CAR-T cell therapy created using CRISPR/Cas9 technology for patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL).
CD19 is the earliest differentiation antigen of the B lineage and is ubiquitously expressed on all types of B lymphocytes except plasma cells, thereby representing an attractive target for B-cell non-Hodgkin lymphomas (NHL) or leukemia of B-cell origin.
Defect: Cancer/Lymphoma
Treatment Approach: CB-010 is an off-the-shelf allogeneic anti-CD19, CAR-T cell therapy created using CRISPR/Cas9 technology for patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL).
Clinical Stage: Phase 1/2 (IND cleared
